Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-17: Gemtuzumab ozogamicin plus intensive chemotherapy vs intensive chemotherapy alone in older untreated AML
2005-001347-37Phase 3Completed
- Sponsor
- GIMEMA
- Start
- Aug 2006
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by GIMEMA. Started Aug 2006; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-001347-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001347-37.